🍀Proposed Acquisition of Shire plc by Takeda
Transaction HighlightsBrings together complementary positions in gastroenterology (GI) and neuroscience; provides leading positions in rare diseases and plasma-derived therapies to complement strength in oncology and focused efforts in vaccines
Creates a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, with an attractive geographic footprint and provides the scale to drive future development
Creates a highly complementary, robust, modality-diverse pipeline and a strengthened R&D engine focused on breakthrough innovation
Enhances Takeda’s cash flow profile, with management confident of delivering substantial annual cost synergies and generating attractive returns for shareholders
Takeda’s transformation positions the combined group to successfully integrate Shire and maximize value from the combination
https://www.takeda.com/newsroom/newsreleases/2018/proposed-acquisition-of-shire-plc-by-takeda/
Japan’s Takeda Agrees to Buy Shire for 46 B. Pounds – JIJI PRESS